NO933341L - Fordindelser mot kreft - Google Patents

Fordindelser mot kreft

Info

Publication number
NO933341L
NO933341L NO933341A NO933341A NO933341L NO 933341 L NO933341 L NO 933341L NO 933341 A NO933341 A NO 933341A NO 933341 A NO933341 A NO 933341A NO 933341 L NO933341 L NO 933341L
Authority
NO
Norway
Prior art keywords
carbon atoms
alkyl
alkoxy
hydroxy
halogen
Prior art date
Application number
NO933341A
Other languages
English (en)
Norwegian (no)
Other versions
NO933341D0 (no
Inventor
Graham Michael Fraser Bisset
Ann Lesley Jackman
Duncan Ian Jodrell
Original Assignee
British Tech Group
Ici Plc
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group, Ici Plc, Ici Ltd filed Critical British Tech Group
Publication of NO933341D0 publication Critical patent/NO933341D0/no
Publication of NO933341L publication Critical patent/NO933341L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO933341A 1991-03-19 1993-09-20 Fordindelser mot kreft NO933341L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105771A GB9105771D0 (en) 1991-03-19 1991-03-19 Anti-cancer compounds
PCT/GB1992/000476 WO1992016512A1 (en) 1991-03-19 1992-03-18 Anti-cancer compounds

Publications (2)

Publication Number Publication Date
NO933341D0 NO933341D0 (no) 1993-09-20
NO933341L true NO933341L (no) 1993-11-18

Family

ID=10691801

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933341A NO933341L (no) 1991-03-19 1993-09-20 Fordindelser mot kreft

Country Status (18)

Country Link
US (1) US5444061A (cg-RX-API-DMAC10.html)
EP (1) EP0509643A1 (cg-RX-API-DMAC10.html)
JP (1) JPH06505974A (cg-RX-API-DMAC10.html)
AU (1) AU655970B2 (cg-RX-API-DMAC10.html)
CA (1) CA2106583A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ195393A3 (cg-RX-API-DMAC10.html)
FI (1) FI934106A7 (cg-RX-API-DMAC10.html)
GB (2) GB9105771D0 (cg-RX-API-DMAC10.html)
HU (1) HUT67177A (cg-RX-API-DMAC10.html)
IE (1) IE920853A1 (cg-RX-API-DMAC10.html)
IL (1) IL101281A0 (cg-RX-API-DMAC10.html)
MX (1) MX9201183A (cg-RX-API-DMAC10.html)
NO (1) NO933341L (cg-RX-API-DMAC10.html)
NZ (1) NZ242023A (cg-RX-API-DMAC10.html)
SK (1) SK100993A3 (cg-RX-API-DMAC10.html)
TW (1) TW203608B (cg-RX-API-DMAC10.html)
WO (1) WO1992016512A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA921985B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9205907D0 (en) * 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
US20030236430A1 (en) * 2002-06-21 2003-12-25 Allen David Robert Preparation of protected amino acids
WO2004009036A2 (en) 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−4−オン化合物、組成物、および方法
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
EP1692112A4 (en) * 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
TR201901010T4 (tr) 2007-04-11 2019-02-21 Merck & Cie 18F etiketli folatlar.
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
US4746659A (en) * 1985-12-30 1988-05-24 Sri International Diastereomers of 10-alkyl-10-deazaminopterins and process for preparing the same
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8625019D0 (en) * 1986-10-18 1986-11-19 Wellcome Found Compounds
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4767761A (en) * 1987-11-04 1988-08-30 Dana-Farber Cancer Institute, Inc. Ornithine derivatives and their use as methotrexate-resistant cell inhibitors
GB8727737D0 (en) * 1987-11-26 1987-12-31 Ici Plc Antitumour agents
GB8809978D0 (en) * 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
US5252573A (en) * 1988-12-15 1993-10-12 Imperial Chemical Industries Plc Anti-tumor agents
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
DE69111891T2 (de) * 1990-05-17 1996-04-04 Smith & Nephew United Inc Elektrisch leitender und adstringierender Film sowie filmbildende Zusammensetzung zur Verwendung auf der Haut.
AU640016B2 (en) * 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives

Also Published As

Publication number Publication date
HUT67177A (en) 1995-02-28
CA2106583A1 (en) 1992-09-20
ZA921985B (en) 1993-09-20
FI934106A7 (fi) 1993-11-18
MX9201183A (es) 1994-06-30
JPH06505974A (ja) 1994-07-07
SK100993A3 (en) 1994-08-10
NZ242023A (en) 1993-12-23
TW203608B (cg-RX-API-DMAC10.html) 1993-04-11
GB2253849A (en) 1992-09-23
GB2253849B (en) 1995-01-18
IL101281A0 (en) 1992-11-15
FI934106A0 (fi) 1993-09-20
AU655970B2 (en) 1995-01-19
CZ195393A3 (en) 1994-07-13
WO1992016512A1 (en) 1992-10-01
GB9105771D0 (en) 1991-05-01
IE920853A1 (en) 1992-09-23
EP0509643A1 (en) 1992-10-21
AU1371692A (en) 1992-10-21
US5444061A (en) 1995-08-22
HU9302636D0 (en) 1993-12-28
GB9205906D0 (en) 1992-04-29
NO933341D0 (no) 1993-09-20

Similar Documents

Publication Publication Date Title
US4248883A (en) 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds
CA2140598A1 (en) Prolineamide derivatives
US4692458A (en) Anti-hypertensive agents
KR870007205A (ko) 펩티딜아미노디올
KR890013035A (ko) 인돌로카르바졸 유도체와 그 제조방법 및 그들을 함유하는 약제조성물
DE69427800D1 (de) Methode zur Hemmung der Endometriose
MX9201183A (es) Quinazolinas, procedimiento para su obtencion y composicion farmaceutica que las contiene.
KR870007204A (ko) 작용화 펩티딜 아미노디올 및-트리올
SE8802790D0 (sv) Tripeptider med immunostimulerande och metastasforhindrande verkan
KR950703554A (ko) 피페라진 유도체 및 그의 염(piperazine derivatives and salts thereof)
RU2001113268A (ru) Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с
GB9215844D0 (en) Novel compounds
FR2610934B1 (fr) Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR870007164A (ko) 모노술팍탐
KR930007914A (ko) 제1위치에 에테르 또는 티오에테르 그룹을 함유하는 프탈라진 및 이의 제조방법
DK384485D0 (da) 1,6-naphthyridinderivater med kardilaterende virkning
HRP920948A2 (en) Nitratoalkanecarbone acid derivatives, process for the preparation thereof, the use of the same and drugs containing them
KR830008998A (ko) N-치환된-아미노-아미노산의 제조방법
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
EA199800464A1 (ru) Синергическая иммуносупрессорная композиция, содержащая 2,2'-би-1н-пиррольное соединение
US4734420A (en) Anti-hypertensive agents
EA199800085A1 (ru) Способ лечения боли висцерального происхождения, способ лечения воспалительного колита
RU93057568A (ru) Производные хиназолина, способ их получения, способ лечения
RU2001121195A (ru) ((Аминоиминометил)амино)алканкарбоксидамиды и их применение в терапии
SU1433958A1 (ru) 2-Оксо-4-(о-дифторметилтиофенил)-5-метоксикарбонил-6-метил-1,2,3,4-тетрагидропиримидин, обладающий коронарорасшир ющим действием